Table 2.
Pre-clinical studies of chemokine inhibition in cancer.
| Target | Molecule | Cancer Type | References |
|---|---|---|---|
| CCR1 | CCX721 | Multiple myeloma | [94] |
| BL5923 | Colon cancer | [95] | |
| CCX9588 + PD-L1 | Breast cancer | [96] | |
| UCB35625 | Ovarian cancer | [97] | |
| CCR2 | PF-04136309 | Pancreatic cancer | [98] |
| CCX872 + anti-PD-1/PD-L1 | Pancreatic cancer | [99] | |
| RDC018 | Hepatocellular carcinoma | [100] | |
| 747 + Sorafenib | Hepatocellular carcinoma | [101] | |
| CCR4 | Affi-5 (anti-CCR4 mab) | Renal cell carcinoma | [102] |
| Anti-CCR4 CAR-T cells | T-cell malignancies | [103] | |
| AF399/420/1802 + vaccine + temsirolimus | Melanoma, lung and colon cancer | [104] | |
| CCR5 | Maraviroc and vicriviroc | Basal breast cancer | [105,106] |
| Prostate cancer | [107] | ||
| Leronlimab | Breast cancer | [108] | |
| Maraviroc | Acute lymphoblastic leukaemia | [109] | |
| Colorectal cancer | [110] | ||
| TAK-779 | Pancreatic cancer | [111] | |
| Anti-CCR5 mab (559921) | Melanoma | [112] | |
| CCR7 | Anti-CCR7 mab (150503) | T-cell prolymphocytic leukaemia | [113] |
| siRNA | Metastatic colorectal cancer | [114] | |
| Metastatic prostate cancer | [115] | ||
| miRNA | Breast cancer | [116] | |
| CXCR2 | Navarixin + MEK inhibitor | Melanoma | [117] |
| SB225002 + Sorafenib | Ovarian cancer | [118] | |
| SB225002 + Cisplatin | Lung cancer | [119] | |
| Reparixin + 5-FU | Gastric Cancer | [120] | |
| AZ13381758 + Gemcitabine | Pancreatic ductal adenocarcinoma | [121] | |
| SB265610 + Docetaxel | Prostate Cancer | [122] | |
| CXCR4 | Plerixafor (AMD3100) | Acute myeloid leukaemia | [123] |
| Ovarian cancer | [124] | ||
| Colorectal and pancreatic cancer | [125] | ||
| BKT140 + Rituximab | Lymphoma | [126] | |
| AMD 3100/AMD 3465 | Brain cancer | [127] | |
| PRX177561 + bevacizumab + sunitinib | Glioblastoma | [128] | |
| POL5551 + anti-VEGF | Glioblastoma | [129] | |
| AMD3465 | Breast cancer | [130] | |
| LY2510924 | Metastatic breast cancer | [131] | |
| Acute myeloid leukaemia | [132] | ||
| Plerixafor + anti-PD-L1 | Pancreatic cancer | [133] | |
| Plerixafor + VIC-008 | Mesothelioma | [134] | |
| BPRCX807 | Hepatocellular carcinoma | [135] |